Hypophosphatemic Rickets

Hypophosphatemic rickets is a bone disease where the body loses too much phosphate in the urine. Phosphate is a mineral your bones need to harden and stay strong. In the most common type (XLH), a hormone called FGF23 is too high. This hormone tells the kidneys to throw away phosphate and also lowers the body’s active vitamin D level. The result is soft, weak bones, leg bowing, short stature in children, bone pain, muscle weakness, and dental problems. Standard care used to be many daily doses of oral phosphate plus active vitamin D to “replace what is wasted.” Now, a newer treatment called burosumab blocks FGF23 and helps the kidneys hold on to phosphate, raising blood phosphate and active vitamin D to healthier levels. Merck Manuals+2PMC+2

Hypophosphatemic rickets is a bone disease where the body does not keep enough phosphate in the blood. Phosphate is a mineral that bones need to harden and grow. In this condition, the kidneys lose too much phosphate in the urine (called renal phosphate wasting). Because of the low phosphate, a child’s growing bone plates (growth plates) do not mineralize properly. Bones bend, growth slows, legs may bow, and teeth and muscles can be affected. In adults, the same problem causes soft bones (osteomalacia), bone pain, and tendon and ligament problems (enthesopathy). Most cases are not due to lack of vitamin D, and sunlight or usual vitamin D capsules do not fix it, because the core problem is phosphate loss and hormone signals that lower phosphate (especially FGF23). PMC+2OUP Academic+2

Other names

• FGF23-related hypophosphatemic rickets/osteomalacia – emphasizes the hormone (FGF23) that causes kidney phosphate wasting in many forms. jme.bioscientifica.com

• Vitamin D–resistant rickets – an older, less precise term; these conditions do not improve with usual vitamin D alone. Medscape Reference

• X-linked hypophosphatemia (XLH) – the most common inherited form; often used when this particular genetic type is confirmed. NCBI+1

Types

1. Inherited (genetic) FGF23-mediated types
   These are due to gene changes that ultimately raise FGF23 or increase its action. FGF23 lowers blood phosphate by making the kidneys waste phosphate and by lowering active vitamin D production. Common examples: XLH (PHEX gene), ADHR (FGF23 gene), ARHR due to DMP1, ENPP1, FAM20C, and some other rare genes. All share chronic low phosphate and rickets/osteomalacia. OUP Academic+1

2. Inherited non-FGF23 (renal phosphate transport) types
   Here the kidney transporters that reclaim phosphate are defective (for example SLC34A3 in hereditary hypophosphatemic rickets with hypercalciuria). These may have different lab patterns (often low FGF23, high urine phosphate, sometimes higher active vitamin D and kidney stones). PMC

3. Acquired (non-genetic) FGF23-mediated types
   The classic cause is tumor-induced osteomalacia (TIO), where a small benign tumor makes excess FGF23. Removing the tumor corrects the problem. Some bone disorders (e.g., fibrous dysplasia) can also raise FGF23. jme.bioscientifica.com

4. Acquired renal phosphate-wasting (non-FGF23) types
   Fanconi syndrome (global proximal tubule dysfunction) from toxins, drugs, or diseases can cause phosphate loss and rickets/osteomalacia. NCBI

Big picture: No matter the type, the shared pathway is kidney phosphate wasting → low blood phosphate → poor bone mineralization. The details (genes, hormones, and associated features) help doctors tell the types apart. PMC

Causes

1. X-linked hypophosphatemia (XLH; PHEX variants)
   Most common inherited cause. The PHEX defect leads to high FGF23, kidney phosphate loss, low or inappropriately normal active vitamin D, and rickets beginning in early childhood. Dental abscesses and short stature are common. NCBI

2. Autosomal dominant hypophosphatemic rickets (ADHR; FGF23)
   Mutations make FGF23 harder to break down, so it stays high. Age at onset varies—childhood or adulthood—with episodes sometimes linked to iron status. OUP Academic

3. Autosomal recessive hypophosphatemic rickets (ARHR1; DMP1)
   DMP1 defects raise FGF23. Children develop rickets, growth delay, and dental problems. OUP Academic

4. ARHR2 (ENPP1)
   ENPP1 changes elevate FGF23; can be associated with abnormal calcifications in tissues and vascular problems. OUP Academic

5. ARHR3 (FAM20C)
   FAM20C affects bone mineralization and FGF23 processing; children show rickets and dental anomalies. OUP Academic

6. Hereditary hypophosphatemic rickets with hypercalciuria (HHRH; SLC34A3)
   A kidney phosphate transporter is defective (not FGF23-driven). Low phosphate triggers high active vitamin D and high urine calcium, sometimes causing stones. PMC

7. SLC34A1-related hypophosphatemia
   Another phosphate transporter problem; similar renal phosphate wasting phenotype, sometimes with kidney calcifications. PMC

8. Tumor-induced osteomalacia (TIO)
   Small mesenchymal tumors secrete excess FGF23, causing profound phosphate loss and adult osteomalacia with fractures and severe pain; cure is tumor removal. jme.bioscientifica.com

9. Fibrous dysplasia / McCune–Albright syndrome
   Abnormal bone lesions overproduce FGF23, leading to hypophosphatemia and bone pain/deformity. jme.bioscientifica.com

10. Iron-related modulation of FGF23
    Iron deficiency and some intravenous iron formulations can change FGF23 production or processing, sometimes lowering phosphate enough to cause osteomalacia. OUP Academic

11. Ifosfamide-induced Fanconi syndrome
    Chemotherapy can damage proximal tubules, causing phosphate (and other solute) loss; children can develop rickets. NCBI

12. Tenofovir-associated Fanconi syndrome
    Rarely, this antiviral injures proximal tubules resulting in phosphate wasting and osteomalacia. NCBI

13. Heavy metal toxicity (e.g., cadmium) → Fanconi syndrome
    Proximal tubular injury leads to phosphate loss and rickets in severe or chronic exposure. NCBI

14. Cystinosis-related Fanconi syndrome
    A genetic storage disease that injures proximal tubules; children have generalized solute wasting including phosphate, causing rickets. NCBI

15. Wilson disease with tubular dysfunction
    Copper overload can impair proximal tubules and contribute to phosphate wasting. NCBI

16. Primary hyperparathyroidism (rare pediatric cases)
    High PTH lowers phosphate reabsorption; long-standing cases can contribute to rickets/osteomalacia in growing children. NCBI

17. Oncologic proximal tubule injury (post-transplant calcineurin inhibitors—rare)
    Occasional medication-related Fanconi-like states can waste phosphate. NCBI

18. Dent disease
    An X-linked proximal tubulopathy with low-molecular-weight proteinuria and phosphate wasting; can lead to rickets. NCBI

19. Expired or counterfeit traditional medicines with nephrotoxins
    Unregulated products can injure proximal tubules and cause Fanconi-type phosphate loss. NCBI

20. Post-bariatric surgery malabsorption with secondary renal phosphate loss (uncommon)
    Severe malabsorption states can contribute to chronic low phosphate and osteomalacia; less typical for true hypophosphatemic rickets but can overlap. NCBI

Common symptoms and signs

1. Bowed legs or knock-knees
   Because growth plates cannot harden, leg bones bend under body weight once the child starts walking. Shape depends on age and mechanics. PMC

2. Short stature or slow growth
   Children may drop on the growth chart after the first year of life due to chronic poor mineralization of growth plates. Frontiers

3. Waddling gait and delayed walking
   Weak hips and soft femurs make walking late and “waddly.” Parents may first notice a wide-based, side-to-side gait. Frontiers

4. Bone pain and tenderness
   The soft, undermineralized bone is painful with activity and at night. Adults describe deep, aching pain. PMC

5. Muscle weakness (especially proximal muscles)
   Phosphate is crucial for energy in muscle cells. Low phosphate causes easy fatigue and weakness. PMC

6. Dental problems (spontaneous dental abscesses)
   Children can have abscesses without cavities or trauma because dentin is poorly mineralized and cracks allow infection. Pediatric Endocrine Society

7. Large wrists/ankles (rachitic swelling)
   Growth plate widening makes the metaphyses look flared and lumpy at wrists and ankles. PMC

8. Head shape changes (craniosynostosis) and forehead bossing
   Premature fusion of skull sutures (especially sagittal) can change head shape and sometimes raise intracranial pressure. NCBI

9. Chest deformities (rachitic rosary, pectus changes)
   Poor rib mineralization can cause bumpy costochondral junctions and chest wall changes. PMC

10. Spinal curvature (kyphosis/scoliosis)
    Soft vertebrae can gradually deform, adding to back pain. PMC

11. Fractures or pseudofractures (Looser zones) in adults
    Adults with long-standing disease get stress fractures in ribs, pelvis, or femur. PMC

12. Enthesopathy (painful tendon/ligament insertions) in adults
    Chronic mineral imbalance promotes calcified entheses, causing stiffness and pain. OUP Academic

13. Hearing problems (occasional)
    Some adults with XLH report conductive or mixed hearing loss due to bone changes in the ear. OUP Academic

14. Fatigue and low exercise tolerance
    Energy demand rises when muscles and bones are weak; patients tire easily. Frontiers

15. Slow teething and enamel defects
    Teeth may erupt late and enamel may be thin or pitted, raising cavity and abscess risk. Pediatric Endocrine Society

Diagnostic tests

A) Physical examination (what the clinician looks for)

1. Growth chart review
   Plot length/height, weight, and head circumference over time. A fall-off in height percentiles after infancy is a red flag for XLH and related types. Frontiers

2. Gait observation
   Waddling or bow-legged walking suggests lower-limb deformity and hip weakness. Frontiers

3. Limb alignment assessment
   Measure genu varum/valgum and tibial torsion. Widened wrists/ankles (rachitic flaring) support active rickets. PMC

4. Dental and oral exam
   Look for enamel defects and abscesses without caries—an important clue for hypophosphatemic rickets. Pediatric Endocrine Society

5. Head and skull exam
   Palpate sutures and check head shape; suspect craniosynostosis in XLH if the sagittal suture is early-fused. NCBI

B) Manual/bedside functional tests (simple clinic maneuvers)

6. Manual muscle testing of hips and shoulders
   Assesses proximal weakness from phosphate-related myopathy. Improvement with treatment supports the diagnosis. PMC

7. Timed up-and-go / stair climb
   Functional tests show reduced endurance and help track response over time. OUP Academic

8. Joint range-of-motion and flexibility exam
   Restricted hips/knees and painful tendon insertions may indicate enthesopathy in older patients. OUP Academic

9. Intercondylar/intermalleolar distance
   A simple measure of knee angulation to follow bowing or knock-knees during growth. PMC

10. Pain mapping and palpation
    Localized bony tenderness over ribs, pelvis, or long bones can suggest stress fractures/Looser zones. PMC

C) Laboratory and pathological tests

11. Serum phosphate (low)
    Key hallmark. Levels are below the normal range for age (note: children’s normal phosphate is higher than adults). NCBI

12. Alkaline phosphatase (usually high in active rickets)
    Reflects increased bone turnover and poor mineralization in growing children; may be variably elevated in adults with osteomalacia. AAP Publications

13. Calcium (often normal) and PTH (normal or mildly high)
    In FGF23-mediated disease, calcium is usually normal and PTH may be normal or slightly elevated. This pattern helps separate from classic vitamin D deficiency rickets. PMC

14. 25-hydroxyvitamin D (often normal) and 1,25-dihydroxyvitamin D (low/inappropriately normal)
    FGF23 suppresses kidney 1-alpha hydroxylase, lowering active vitamin D. OUP Academic

15. Urine phosphate and TmP/GFR calculation (low)
    TmP/GFR is the kidney’s maximum reabsorption of phosphate adjusted for filtration; it’s low in renal phosphate wasting. PMC

16. Serum/PLasma FGF23 (elevated in FGF23-mediated disease)
    High FGF23 supports XLH/ADHR/ARHR or TIO; not all labs are standardized, but it is useful with the rest of the picture. jme.bioscientifica.com

17. Urine β2-microglobulin and other Fanconi markers
    If Fanconi syndrome is suspected, look for low-molecular-weight proteinuria, glycosuria with normal blood glucose, aminoaciduria, and bicarbonate loss. NCBI

18. Genetic testing panels
    Confirms hereditary types (PHEX, FGF23, DMP1, ENPP1, FAM20C, SLC34A3/SLC34A1, and others). This guides family counseling and treatment. NCBI

D) Electrodiagnostic and related physiologic tests (used selectively)

19. Electromyography (EMG) in unexplained weakness
    Most patients don’t need EMG, but it can help distinguish true myopathy from deconditioning or nerve problems when symptoms are unclear. PMC

20. Audiology testing
    Some adults with XLH develop conductive or mixed hearing loss; formal hearing tests document baseline and change. OUP Academic

E) Imaging tests

21. X-rays of wrists and knees
    Classic rickets changes include growth-plate widening, cupping, and fraying. In adults, look for Looser zones and stress fractures. PMC

22. Full skeletal survey or targeted radiographs
    Shows leg bowing, hip deformities (coxa vara/valga), and sites of pain. Helpful to plan orthopedic care. PMC

23. Bone age study (hand/wrist)
    Assesses skeletal maturation versus chronological age in children with growth delay. AAP Publications

24. Cranial CT (if craniosynostosis suspected)
    Defines suture fusion and guides neurosurgical referral when needed. NCBI

25. Renal ultrasound (especially during treatment)
    Used to monitor nephrocalcinosis, which can occur in some types and with certain therapies. PMC

26. Dental panoramic radiograph
    Shows dentin/enamel defects and periapical pathology even without cavities—classic for XLH. Pediatric Endocrine Society

Non-pharmacological treatments (therapies and others)

1. Team-based care and education
   Create a personalized plan with endocrinology, nephrology, orthopedics, dentistry, and physical therapy. Education helps families understand why phosphate is low, how to give medicines correctly, and when to seek care for bone pain or dental abscesses. Early, coordinated care improves growth, bone shape, and tooth health. PMC

2. Growth and gait monitoring
   Regular measurements of height/length, leg alignment, gait, and motor skills let the team act early if deformities or weakness appear. Tracking helps decide when bracing, therapy, or surgery is needed, and checks if treatment is working. PubMed

3. Physiotherapy for strength and mobility
   Gentle strengthening, core stability, balance work, and range-of-motion exercises can reduce pain, improve walking, and support posture. A therapist adapts intensity to bone pain and fatigue to avoid stress fractures. PMC

4. Low-impact physical activity
   Activities like walking, swimming, or cycling load bones safely and maintain muscle. Avoid high-impact jumps or intense torsion on bowed limbs until bone strength improves under medical therapy. PMC

5. Orthotics and bracing
   Knee-ankle-foot orthoses or insoles may guide growth and support alignment in children, lowering joint stress and pain as bones mineralize. Bracing is typically paired with medical therapy and monitored by orthopedics. journalbonefragility.com

6. Guided growth (timing preparation)
   Although the hardware is “surgery,” the pathway begins as a non-operative plan—serial imaging and timing decisions for temporary hemiepiphysiodesis to nudge growth plates for straighter legs while the child grows. journalbonefragility.com

7. Fall-prevention training
   Teaching safe transfers, balance drills, home hazard checks, and supportive footwear reduces fracture risk in painful, undermineralized bone. PMC

8. Pain self-management skills
   Heat/cold packs, pacing activity, relaxation breathing, and sleep hygiene can lower daily discomfort while definitive therapy improves mineralization. Avoid frequent NSAIDs without clinician advice because of kidney considerations. PMC

9. Nutrition counseling (balanced calcium, phosphorus, protein)
   A dietitian helps match calcium and total nutrition to therapy goals without excesses that could raise the calcium-phosphate product too much (a risk with high phosphate dosing). Diet supports bone repair while medicines correct the cause. Merck Manuals

10. Dental care program
    Regular checkups, early caries care, sealants when appropriate, and prompt treatment of dental abscesses limit tooth pain and infections that are common in XLH. PMC

11. Sunlight and routine vitamin D intake (supportive only)
    Unlike “nutritional rickets,” sunlight or plain vitamin D alone does not fix HR, because the problem is phosphate wasting. Still, ensuring general vitamin D sufficiency (per clinical guidance) supports overall bone health. Medscape Reference

12. Ergonomic adjustments at school/work
    Extra rest breaks, ergonomic seating, and reduced load carrying can cut daily bone stress while treatment rebuilds mineralization. PMC

13. Psychosocial support
    Chronic pain, short stature, and repeated procedures can affect mood and confidence. Counseling and peer groups help children and adults cope and stick with long-term care plans. PMC

14. Home safety and assistive devices
    Grab bars, railings, shower seats, and mobility aids reduce falls and ease daily tasks during periods of bone pain or after surgery. PMC

15. School/IEP coordination
    For children, a 504/IEP plan can allow rest, elevator use, or modified physical education to prevent overuse injuries while growth and alignment improve. PMC

16. Weight management
    Maintaining a healthy weight lowers joint load on bowed legs and painful hips/knees and may reduce future osteoarthritis risk. journalbonefragility.com

17. Avoid nephrotoxins
    Limit or avoid drugs that stress the kidney (e.g., some NSAIDs) and ensure hydration, especially when on phosphate and calcitriol or if kidney function is borderline. Merck Manuals

18. Regular labs and imaging surveillance
    Consistent monitoring of fasting serum phosphate, calcium, PTH, 1,25-dihydroxyvitamin D, renal function, and periodic radiographs ensure therapy is effective and safe. PMC

19. Genetic counseling (when indicated)
    Families with XLH may benefit from counseling about inheritance patterns, testing options, and planning for future pregnancies. OUP Academic

20. Pre-/post-operative rehab planning
    When deformity surgery is needed, prehab builds strength and post-op rehab restores motion and function to get the most from the correction. PubMed

---

Drug treatments

Only burosumab is FDA-approved to treat the cause of XLH by blocking FGF23. Calcitriol has an FDA label (for other indications) and is commonly used off-label with oral phosphate in HR/XLH. Oral phosphate products are often listed on DailyMed but carry disclaimers that the specific products are not FDA-approved; doctors still use phosphorus replacement as part of standard care. I’ll clearly mark FDA label sources for each medicine. FDA Access Data+2FDA Access Data+2

1. Burosumab-twza (CRYSVITA®) — FGF23 antibody
   Class & Purpose: Human monoclonal antibody that binds FGF23 to raise serum phosphate and increase 1,25-dihydroxyvitamin D, correcting the main defect in XLH. Dose & Time: Subcutaneous injection every 2–4 weeks; pediatric and adult dosing is weight-based. Mechanism: Restores renal phosphate reabsorption and boosts active vitamin D production. Side effects: Injection-site reactions, headache; monitoring of phosphate and calcium is required; label advises stopping oral phosphate/active vitamin D one week before start. FDA label source: accessdata.fda.gov. FDA Access Data+1

2. Calcitriol (Rocaltrol®) — active vitamin D analog (off-label for HR/XLH; FDA-labeled for other uses)
   Class & Purpose: Active vitamin D that helps gut absorb calcium and supports mineralization; used with oral phosphate to counter low 1,25-D seen in HR. Dose & Time: Microgram doses (e.g., 0.25–0.5 mcg/day; individualized); careful lab monitoring is essential. Mechanism: Raises calcium absorption and, with phosphate, improves bone mineralization. Side effects: Hypercalcemia, hypercalciuria—so dosing and labs are tightly controlled. FDA label source: Rocaltrol labeling on accessdata.fda.gov. FDA Access Data+1

3. Oral phosphate (e.g., K-Phos Neutral / Phospha 250 Neutral) (commonly used; DailyMed notes many such products are not FDA-approved)
   Class & Purpose: Phosphate replacement to raise low serum phosphate. Dose & Time: Multiple small doses daily because phosphate is quickly cleared; prescriber sets dosing based on age, weight, and labs. Mechanism: Provides the mineral needed for bone hardening. Safety: Must combine with active vitamin D and monitor calcium, PTH, urinary calcium to avoid secondary hyperparathyroidism and kidney issues. DailyMed note: labeling includes an FDA non-approval disclaimer. DailyMed+3PMC+3Merck Manuals+3

4. Alfacalcidol (active vitamin D prodrug; not an FDA-approved drug in the U.S.; used in other regions)
   Purpose/Mechanism: Converted to calcitriol in the liver; used similarly to calcitriol with phosphate in traditional regimens. Evidence: Practice recommendations describe its use alongside phosphate to prevent complications. Safety: Hypercalcemia risk similar to calcitriol; requires close monitoring. PMC

5. Cholecalciferol/Ergocalciferol (Vitamin D3/D2) — supportive only
   Purpose/Mechanism: Corrects background vitamin D deficiency but does not treat phosphate wasting; used to keep vitamin D sufficient while disease-targeted therapy proceeds. Safety: Avoid excessive dosing; follow guidelines. Medscape Reference

6. Phosphate binders (contextual caution, not routine for HR)
   These agents (e.g., calcium acetate, sevelamer) lower phosphate absorption and are used in hyperphosphatemia, not HR. They are generally not used in HR because HR patients are phosphate-deficient; I include them only to clarify they’re inappropriate in this setting. FDA Access Data

7. Pain control (acetaminophen preferred)
   For bone pain, acetaminophen is preferred; avoid frequent NSAIDs without clinician guidance because of kidney considerations, especially in a condition with renal phosphate handling issues and in those using phosphate therapy. Merck Manuals

8. Dental antibiotics when indicated
   Dental abscesses are common in XLH; antibiotics are used when clinically indicated, alongside dental procedures. This is supportive management rather than disease-modifying therapy. PMC

9. Peri-operative medication planning
   When corrective osteotomy is scheduled, teams plan pain control, thromboprophylaxis if needed, and temporary adjustments to phosphate/vitamin D/burosumab to support healing. PubMed

10. Management of drug-induced phosphate wasting (e.g., tenofovir)
    In acquired hypophosphatemia from medications such as tenofovir, stopping or switching the offending agent and correcting mineral/vitamin D can reverse osteomalacia. This is not XLH, but the principle is relevant to the broader “hypophosphatemic” spectrum. PMC+1

For XLH/HR, there is one FDA-approved disease-modifying drug—burosumab—and supportive agents (calcitriol with phosphate) that have labels for other indications or are not FDA-approved products. Listing “20 FDA-sourced drugs for HR” would be inaccurate and potentially unsafe. I’ve therefore provided the correct, evidence-based set with clear FDA labeling where it truly exists. FDA Access Data+1

---

Dietary molecular supplements

Important note: Supplements do not correct FGF23-driven phosphate wasting. They may support general bone health in addition to prescribed medical therapy. Avoid large, unsupervised doses that could raise risk (e.g., high calcium while on calcitriol). Merck Manuals

1. Calcium (diet-guided, supplement only if needed)
   Supports bone mineralization but must be balanced against risk of hypercalcemia/hypercalciuria when taking calcitriol. Use only as directed by your clinician with regular labs. Merck Manuals

2. Vitamin D (D3) to maintain sufficiency
   Maintains general bone health; does not fix HR. Your team will target a safe 25-OH vitamin D level while monitoring calcium and phosphate. Medscape Reference

3. Magnesium (if low)
   Low magnesium can worsen muscle cramps and affect vitamin D metabolism; replete only if deficiency is documented. PMC

4. Protein-adequate diet
   Aids healing after surgery and supports muscle strength, which protects painful joints. Balanced intake is preferred over high-dose powders unless advised. PMC

5. Phosphorus-containing foods (with medical guidance)
   Food sources contribute phosphate naturally, but diet alone usually cannot overcome renal wasting; intake should align with your prescribed regimen. PMC

6. Omega-3 fatty acids
   General anti-inflammatory support for joint discomfort; not disease-modifying for HR. Use food sources or supplements per clinician advice. PMC

7. B-complex (if poor intake)
   Corrects diet-related deficiencies that can worsen fatigue; not specific to HR. PMC

8. Iron (only if deficient)
   Treat iron deficiency that can add fatigue and impair rehab; check ferritin and transferrin saturation before supplementing. PMC

9. Zinc (if deficient)
   Supports growth and tissue repair; supplement only with confirmed deficiency to avoid copper imbalance. PMC

10. Adequate fluids
    Hydration supports kidney health, especially when on therapies that change mineral handling. Merck Manuals

---

Immunity booster / regenerative / stem cell drugs

There are no FDA-approved “immunity boosters,” regenerative drugs, or stem-cell drugs for XLH/HR. Using such products outside clinical trials is not recommended. The correct, labeled disease-modifying therapy is burosumab; traditional supportive therapy uses calcitriol (labeled for other indications) with oral phosphate (often not FDA-approved products). If you hear claims about “stem cell fixes” for XLH/HR, ask for peer-reviewed evidence and FDA authorization; at present, there are none. FDA Access Data+1

---

Surgeries

1. Guided growth (temporary hemiepiphysiodesis)
   A small implant on one side of the growth plate guides the limb to straighten over time in growing children. It’s chosen when deformity is moderate and there is enough growth remaining to remodel alignment. journalbonefragility.com

2. Corrective osteotomy (acute correction)
   The surgeon cuts and realigns the bone in one operation and stabilizes it with plates or rods. This is used for more severe deformities or when growth is limited. PubMed

3. Gradual correction with external fixation
   Frames slowly adjust bone alignment over weeks. This is used for complex, multi-apical deformities to fine-tune alignment with less soft-tissue strain. PubMed

4. Combined femoral and tibial osteotomies
   For severe varus or valgus affecting both thigh and shin bones, staged or single-session combined corrections may be needed to restore mechanical axis and gait. ScienceDirect

5. Dental surgical care
   Incision and drainage of abscesses, root canal therapy, or extractions when necessary help control infection and pain common in XLH dentin defects. PMC

---

Preventions

1. Start treatment early and keep regular follow-ups; early therapy improves rickets healing and growth. PMC

2. Take medicines exactly as prescribed; splitting phosphate doses and timing calcitriol reduces side effects. PMC

3. Get scheduled labs (phosphate, calcium, PTH, kidney function, vitamin D) to catch problems early. PMC

4. Maintain routine dental visits and prompt care for tooth pain or swelling. PMC

5. Use physiotherapy and safe activity to strengthen muscles and protect joints. PMC

6. Avoid nephrotoxic medicines unless essential and monitored. Merck Manuals

7. Keep vitamin D sufficient (per clinician guidance), but don’t self-dose large amounts. Medscape Reference

8. Follow surgical timing if recommended; delay may worsen joint wear. PubMed

9. For medication-induced phosphate wasting (e.g., tenofovir), ask about safer alternatives. PMC

10. Coordinate school/work supports to reduce injury risk and fatigue. PMC

---

When to see doctors

See your care team urgently for new or worsening bone pain, sudden limping, obvious limb bowing, dental abscess signs (tooth pain with swelling/fever), muscle weakness that limits walking, or after a significant fall. Also seek care if you miss several doses of medicines, if you have vomiting/diarrhea that could change mineral balance, or if you start a new medication that may affect kidneys. Routine visits every few months are needed for labs and dose adjustments in growing children, and regularly for adults. PMC

---

What to eat and what to avoid

1. Eat balanced meals with adequate protein, fruits/vegetables, and whole grains to support healing. PMC

2. Meet, don’t exceed, calcium targets your clinician sets, especially if you take calcitriol. PubMed

3. Get reasonable phosphorus from foods (dairy, meats, legumes) but follow your doctor’s plan; diet alone won’t fix HR. PMC

4. Stay hydrated to support kidney health during therapy. Merck Manuals

5. Limit high-phosphate additives only if your clinician advises; in HR, the problem is loss in urine, not intake, so follow the personalized plan. Merck Manuals

6. Avoid mega-dose supplements (calcium or vitamin D) unless prescribed—risk of side effects rises with calcitriol. FDA Access Data

7. Moderate caffeine and soda that displace nutrient-dense foods. PMC

8. Lean proteins (fish, poultry, legumes) help muscle support for painful joints. PMC

9. If surgery is planned, follow prehab nutrition guidance to aid bone healing. PubMed

10. If you take phosphate products, follow timing instructions carefully to avoid stomach upset and improve absorption. PMC

---

FAQs

1) Is hypophosphatemic rickets the same as vitamin D deficiency rickets?
No. In HR, the kidneys waste phosphate because of high FGF23, so bones stay soft even if you get sun or take vitamin D. Nutritional rickets is different and often responds to vitamin D and calcium. OUP Academic

2) What is the main cause of XLH?
Most XLH is due to PHEX gene variants that raise FGF23. High FGF23 lowers blood phosphate and active vitamin D. OUP Academic

3) How does burosumab work?
It’s an antibody that binds FGF23. This lets the kidneys reabsorb phosphate again and increases 1,25-dihydroxyvitamin D. FDA Access Data

4) Do I still need phosphate and calcitriol if I start burosumab?
FDA labeling instructs stopping oral phosphate and active vitamin D one week before starting burosumab; your team will guide you. FDA Access Data

5) Can plain vitamin D or sunlight cure HR?
No. They help overall bone health but do not fix phosphate wasting. Medscape Reference

6) Why are so many phosphate doses split through the day?
Phosphate is cleared quickly. Small, frequent doses limit spikes and side effects while supporting bone mineralization. PMC

7) What side effects should I watch for on calcitriol with phosphate?
Possible high calcium or high urine calcium; labs are checked regularly to adjust doses. Merck Manuals

8) Is there surgery to straighten legs?
Yes—guided growth during childhood or corrective osteotomies for more severe or complex deformity. Timing is individualized. journalbonefragility.com+1

9) Why are dental abscesses common in XLH?
Dentin and enamel mineralization are affected; early dental care lowers risk of infection and tooth loss. PMC

10) Can adults benefit from treatment?
Yes. Adults may have bone pain, fractures, and dental problems that improve with correct therapy; burosumab is approved for adults with XLH. FDA Access Data

11) Is tenofovir-related phosphate wasting the same disease?
No. It is an acquired cause of renal phosphate wasting and osteomalacia. Treating the drug cause and supporting minerals can reverse it. PMC

12) How often do I need labs?
Your team sets the schedule, often every 1–3 months during dose changes, to track phosphate, calcium, PTH, and kidney function. PMC

13) Can I play sports?
Yes, with guidance. Start with low-impact activity and physiotherapy; avoid high-impact jumping until bones strengthen. PMC

14) Will treatment make me taller if I’m a child?
Early, consistent therapy can improve growth compared with no treatment, but final height varies. Surgical and guided-growth methods can also help alignment. PMC

15) Where can I see official drug information?
Burosumab (CRYSVITA®) and calcitriol (Rocaltrol®) FDA labels are available on accessdata.fda.gov; many phosphate tablets on DailyMed carry “not FDA-approved” disclaimers. FDA Access Data+2FDA Access Data+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 07, 2025.